Insider Selling: Pacira Pharmaceuticals Director Unloads 2,500 Shares of Stock (PCRX)
Pacira Pharmaceuticals (NASDAQ:PCRX) Director John Phd Longenecker sold 2,500 shares of Pacira Pharmaceuticals stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $55.55, for a total value of $138,875.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Pacira Pharmaceuticals (NASDAQ:PCRX) traded down 1.69% during mid-day trading on Thursday, hitting $56.52. The stock had a trading volume of 407,170 shares. Pacira Pharmaceuticals has a 52-week low of $17.15 and a 52-week high of $58.22. The stock has a 50-day moving average of $53.24 and a 200-day moving average of $43.37. The company’s market cap is $1.896 billion.
Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its earnings results on Thursday, October 31st. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.05. The company had revenue of $23.30 million for the quarter, compared to the consensus estimate of $22.10 million.
A number of research firms have recently commented on PCRX. Analysts at Wedbush reiterated a “buy” rating on shares of Pacira Pharmaceuticals in a research note to investors on Monday, November 4th. They now have a $59.00 price target on the stock. Separately, analysts at Jefferies Group raised their price target on shares of Pacira Pharmaceuticals from $58.00 to $60.00 in a research note to investors on Monday, November 4th. They now have a “buy” rating on the stock. Finally, analysts at Barclays raised their price target on shares of Pacira Pharmaceuticals from $56.00 to $60.00 in a research note to investors on Friday, November 1st. They now have an “overweight” rating on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $55.20.
Pacira Pharmaceuticals, Inc is a United States-based pharmaceutical company. The Company develops non-opioid products for postsurgical pain control.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.